866-997-4948(US-Canada Toll Free)

Peritoneal Tumor - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Sep 2013

Category :

Oncology

No. of Pages : 69 Pages


Global Markets Directs, \'Peritoneal Tumor Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Peritoneal Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peritoneal Tumor. Peritoneal Tumor Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Peritoneal Tumor.
  • A review of the Peritoneal Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Peritoneal Tumor pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Peritoneal Tumor.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Peritoneal Tumor pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Peritoneal Tumor Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Peritoneal Tumor 8
Peritoneal Tumor Therapeutics under Development by Companies 10
Peritoneal Tumor Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Peritoneal Tumor Therapeutics - Products under Development by Companies 16
Peritoneal Tumor Therapeutics - Products under Investigation by Universities/Institutes 17
Companies Involved in Peritoneal Tumor Therapeutics Development 18
Boehringer Ingelheim GmbH 18
Amgen Inc. 19
Eli Lilly and Company 20
Daiichi Sankyo Company, Ltd 21
Cell Therapeutics, Inc. 22
Marshall Edwards, Inc. 23
CritiTech, Inc. 24
RECEPTA Biopharma S.A. 25
Peritoneal Tumor - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
trebananib - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
paclitaxel poliglumex - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ramucirumab - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
idronoxil - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
nintedanib - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
exatecan mesylate - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
RebmAb-100 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
paclitaxel - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
EGEN-001 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Carcinoembryonic Antigen-Expressing Measles Virus Vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ABT-767 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
²¹²Pb-TCMC-Trastuzumab - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Peritoneal Tumor Therapeutics - Drug Profile Updates 57
Peritoneal Tumor Therapeutics - Discontinued Products 63
Peritoneal Tumor Therapeutics - Dormant Products 64
Peritoneal Tumor - Product Development Milestones 65
Featured News & Press Releases 65
Nov 01, 2010: Synta Announces Gynecologic Oncology Group To Initiate Phase II Clinical Trial Of Elesclomol For Treatment Of Ovarian Cancer 65
Oct 22, 2010: M’s Science Corporation Sells Its HF10 Oncology Business To Takara Bio Inc. 65
Sep 17, 2010: M’s Science Corporation Initiates Exclusive Negotiations With Takara Bio Inc. To Sell Its HF10 Oncology Business 66
Sep 02, 2010: Oncolytics Biotech Announces Phase II Ovarian Cancer Study To Be Conducted By Gynecologic Oncology Group 66
Oct 16, 2009: National Patent Granted For Developmental Product HF 10 67

Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69

List of Table


Number of Products Under Development for Peritoneal Tumor, H2 2013 8
Products under Development for Peritoneal Tumor - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Number of Products under Investigation by Universities/Institutes, H2 2013 12
Comparative Analysis by Late Stage Development, H2 2013 13
Comparative Analysis by Mid Clinical Stage Development, H2 2013 14
Comparative Analysis by Early Clinical Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
Products under Investigation by Universities/Institutes, H2 2013 17
Boehringer Ingelheim GmbH, H2 2013 18
Amgen Inc., H2 2013 19
Eli Lilly and Company, H2 2013 20
Daiichi Sankyo Company, Ltd, H2 2013 21
Cell Therapeutics, Inc., H2 2013 22
Marshall Edwards, Inc., H2 2013 23
CritiTech, Inc., H2 2013 24
RECEPTA Biopharma S.A., H2 2013 25
Assessment by Monotherapy Products, H2 2013 26
Assessment by Stage and Route of Administration, H2 2013 28
Assessment by Stage and Molecule Type, H2 2013 30
Peritoneal Tumor Therapeutics - Drug Profile Updates 57
Peritoneal Tumor Therapeutics - Discontinued Products 63
Peritoneal Tumor Therapeutics - Dormant Products 64

List of Chart


Number of Products under Development for Peritoneal Tumor, H2 2013 8
Products under Development for Peritoneal Tumor - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Products under Investigation by Universities/Institutes, H2 2013 12
Late Stage Products, H2 2013 13
Mid Clinical Stage Products, H2 2013 14
Early Clinical Stage Products, H2 2013 15
Assessment by Monotherapy Products, H2 2013 26
Assessment by Route of Administration, H2 2013 27
Assessment by Stage and Route of Administration, H2 2013 28
Assessment by Molecule Type, H2 2013 29
Assessment by Stage and Molecule Type, H2 2013 30

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *